1. Home
  2. SNT vs CING Comparison

SNT vs CING Comparison

Compare SNT & CING Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Senstar Technologies Ltd.

SNT

Senstar Technologies Ltd.

N/A

Current Price

$2.02

Market Cap

64.6M

ML Signal

N/A

CING

Cingulate Inc.

HOLD

Current Price

$4.76

Market Cap

59.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SNT
CING
Founded
1965
2012
Country
Canada
United States
Employees
N/A
14
Industry
Telecommunications Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Telecommunications
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
64.6M
59.3M
IPO Year
2023
N/A

Fundamental Metrics

Financial Performance
Metric
SNT
CING
Price
$2.02
$4.76
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$34.50
AVG Volume (30 Days)
26.2K
646.9K
Earning Date
04-23-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$19.22
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.91
$3.16
52 Week High
$5.34
$11.89

Technical Indicators

Market Signals
Indicator
SNT
CING
Relative Strength Index (RSI) 19.90 49.10
Support Level N/A $3.34
Resistance Level $2.87 $5.30
Average True Range (ATR) 0.17 0.37
MACD -0.04 0.03
Stochastic Oscillator 7.14 45.92

Price Performance

Historical Comparison
SNT
CING

About SNT Senstar Technologies Ltd.

Senstar Technologies Corp is an international provider of comprehensive physical, video, and access control security products and solutions. The company offers comprehensive solutions for critical sites, which leverage its broad portfolio of homegrown PIDS (Perimeter Intrusion Detection Systems), advanced VMS and SMS (Video Management Software and Security Management Software) with native IVA (Intelligent Video Analytics) security solutions, as well as access control products and technologies. Geographically, the company operates in North America, which derives maximum revenue; Europe; APAC; South and Latin America; and Others.

About CING Cingulate Inc.

Cingulate Inc is a clinical-stage biopharmaceutical company focused on the development of products utilizing its drug delivery platform technology that enables the formulation and manufacture of once-daily tablets of multi-dose therapies, with an initial focus on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety. The Company is developing two proprietary, first-line stimulant medications, CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine), for the treatment of ADHD intended for all patient segments: children, adolescents, and adults. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic areas to use PTR technology to develop future product candidates.

Share on Social Networks: